Nab-paclitaxel: A flattering facelift

Critical Reviews in Oncology/Hematology

Volumn 92, Issue 3, 2014, Pages 166-180

  Viudez A ^a,b   Ramirez N ^c   Hernandez Garcia I ^a   Carvalho, F L ^b   Vera, R ^a   Hidalgo, M ^d  

^a Instituto de Investigación Sanitaria de Navarra   (Spain)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c Atención Primaria Y Promoción de La Salud   (Spain)

^d Structural Biology and Biocomputing Programme   (Spain)

Author keywords

Breast cancer; Nab paclitaxel; Nanomedicine; Nanotechnology; Pancreatic cancer; SPARC

Indexed keywords

ALBUMIN; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; IXABEPILONE; NANOPARTICLE; OBLIMERSEN; OSTEONECTIN; OXALIPLATIN; PACLITAXEL; TEMOZOLOMIDE; TRASTUZUMAB; VANDETANIB; 130-NM ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

BLADDER CARCINOMA; BLOOD TOXICITY; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TRANSPORT; DRUG TUMOR LEVEL; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; EVENT FREE SURVIVAL; HUMAN; LEUKOPENIA; LUNG CANCER; LUNG SQUAMOUS CELL CARCINOMA; MACULOPAPULAR RASH; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; METASTATIC MELANOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NANOMEDICINE; NANOTECHNOLOGY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PERITONEUM CANCER; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; RECURRENCE FREE SURVIVAL; REVIEW; SEPSIS; STOMACH CANCER; TIME TO MAXIMUM PLASMA CONCENTRATION; TRIPLE NEGATIVE BREAST CANCER; VISCERAL METASTASIS; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG SCREENING; NEOPLASMS; TRANSPORT AT THE CELLULAR LEVEL; TREATMENT OUTCOME;

ALBUMINS; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BIOLOGICAL TRANSPORT; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; NANOMEDICINE; NEOPLASMS; PACLITAXEL; TREATMENT OUTCOME;

EID: 84912529941     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.06.001     Document Type: Review

References (123)

1. Lozano R., Naghavi M., Foreman K., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study. Lancet 2012, 380(9859):2095-2100.
2. WHO. Global status report on NCDs; 2010. [cited 13 03 12]. http://www.who.int/gho/ncd/mortality_morbility/cancer_text/en/index.html.
3. Hájek R., Vorlicek J., Slavik M. Paclitaxel (Taxol): a review of its antitumour activity in clinical studies. Mini-review. Neoplasma 1996, 43:141-154.
4. Parness J., Horwitz S.B. Taxol binds to polymerized tubulin in vitro. J Cell Biol 1981, 479-487.
5. Authier N., Gillet J.P., Fialip J., et al. Assessment of neurotoxicity following repeated cremophor/ethanol injections in rats. Neurotox Res 2001, 3:301-306.
6. Postma T.J., Vermorken J.B., Liefting A.J.M., et al. Paclitaxel-induced neuropathy. Ann Oncol 2004, 6:484-494.
7. Brat D.J., Windebank A.J., Brimijoin S. Emulsifier for intravenous cyclosporine inhibits neurite outgrowth, causes deficits in rapid axonal transport and leads to structural abnormalities in differentiating N1E.115 neuroblastoma. J Pharmacol Exp Ther 1992, 261:803-810.
8. Vader P., Fens M.H., Sachini N., et al. Taxol(®)-induced phosphatidylserine exposure and microvesicle formation in red blood cells is mediated by its vehicle Cremophor(®) EL. Nanomedicine (Lond) 2013, 8(7):1127-1135.
9. Desai N. Challenges in development of nanoparticle-based therapeutics. AAPS J 2012, 14:282-295.
10. Alexis F., Pridgen E., Molnar L.K., et al. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008, 5:505-515.
11. Wang J., Byrne J.D., Napier M.E., et al. More effective nanomedicines through particle design. Small 2011, 7:1919-1920.
12. Fanciullino R., Ciccolini J., Milano G. Challenges, expectations and limits for nanoparticles-based therapeutics in cancer: a focus on nano-albumin-bound drugs. Crit Rev Oncol/Hematol 2013, 88(3):504-513.
13. Zamboni W.C. Liposomal, nanoparticle, and conjugated formulations of anticancer agents. Clin Cancer Res 2005, 11:8230-8240.
14. Zamboni W.C. Concept and clinical evaluation of carrier-mediated anti-cancer agents. Oncologist 2008, 13:248-260.
15. Schnitzer J.E., Oh P. Albondin-mediated capillary permeability to albumin. Differential role of receptors in endothelial transcytosis and endocitosis of native and modified albumin. J Biol Chem 1994, 269:6072-6080.
16. Tiruppathi C., Song W., Bergenfeldt M., et al. Gp60 activation mediates albumin transcytosis in endothelial cells by tyrosin kinase-dependent pathway. J Biol Chem 1997, 272:25968-25970.
17. Kratz F. Albumin as a drug carrier: design of new drugs, drugs conjugates and nanoparticles. J Control Release 2008, 132:171-183.
18. Gradishar W.J. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 2006, 7:1041-1050.
19. Guarneri V., Dieci M.V., Conte P. Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. Expert Opin Pharmacother 2012, 13:395-406.
20. Schubert W., Frank P.G., Razani B., et al. Caveolae-deficient endothelial cells show defects in the uptake and transport of albumin in vivo. J Biol Chem 2001, 276:48619-48620.
21. John T.A., Vogel S.M., Tiruppathi C., et al. Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am J Physiol Lung Cell Mol Physiol 2003, 284:187-196.
22. Uchegbu I.F., Siew A. Nanomedicines and nanodiagnostics come of age. J Pharm Sci 2013, 102:305-310.
23. Marcucci F., Corti A. How to improve exposure of tumour cells to drugs: promoter drugs increase tumour uptake and penetration of effector drugs. Adv Drug Deliv Rev 2012, 64:53-68.
24. Haley B., Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol Oncol 2008, 26:57-64.
25. Bhattacharya R., Mukherjee P. Biological properties of naked metal nanoparticles. Adv Drug Deliv Rev 2008, 60:1289-1290.
26. Garcia-Bennett A., Nees M., Fadeel B. In search of the Holy Grail: folate-targeted nanoparticles for cancer therapy. Biochem Pharmacol 2011, 81:976-984.
27. Gradishar W.J., Tjulandin S., Davidson N., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005, 23:7768-7770.
28. Cortes J., Saura C. Nanoparticle albumin-bound (nab)-paclitaxel: improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer. Eur J Cancer 2010, (Suppl. 8):1-10.
29. Bitounis D., Fanciullino R., Iliadis A., et al. Optimizing druggability through liposomal formulations: new approaches to an old concept. ISRN Pharm 2012, 2012:738432.
30. Desai N., Trieu V., Yao Z., et al. Increased antitumour activity, intratumour paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006, 12:1317-1320.
31. Jain R.K. Normalization of tumour vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
32. Sparreboom A., Van Zuylen L., Brouwer E., et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 1999, 59:1454-1460.
33. Gianni L., Kearns C.M., Giani A., et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995, 13:180-190.
34. Sparreboom A., Scripture C.D., Trieu V., et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albuminbound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res 2005, 11:4136-4140.
35. Ait-Oudhia S., Straubinger R.M., Mager D.E. Meta-analysis of nanoparticulate paclitaxel delivery system pharmacokinetics and model prediction of associated neutropenia. Pharm Res 2012, 29:2833-2840.
36. Ibrahim N.K., Desai N., Legha S., et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002, 8:1038-1040.
37. Yamada K., Yamamoto N., Yamada Y., et al. Phase I and pharmacokinetic study of ABI-007, albumin-bound paclitaxel, administered every 3 weeks in Japanese patients with solid tumours. J Clin Oncol 2010, 40:404-411.
38. Gardner E.R., Dahut W.L., Scripture C.D., et al. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res 2008, 14:4200-4210.
39. Neuzillet C., Tijeras-Raballand A., Cros J., et al. Stromal expression of SPARC in pancreatic adenocarcinoma. Cancer Metastasis Rev 2013, May 21 [Epub ahead of print].
40. Watkins G., Douglas-Jones A., Bryce R., et al. Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins Leukot Essent Fatty Acids 2005, 72:267-272.
41. Koukourakis M.I., Giatromanolaki A., Brekken R.A., et al. Enhanced expression of SPARC/osteonectin in the tumour-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res 2003, 63:5376-5380.
42. Massi D., Franchi A., Borgognoni L., et al. Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum Pathol 1999, 30:339-344.
43. Socinski M.A., Manikhas G.M., Stroyakovsky D.L., et al. A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 2010, 5:852-861.
44. Socinski M.A., Bondarenko I., Karaeva N., et al. Survival results of a randomized, phase 3 trial of nab-paclitaxel and carboplatin compared with cremophor-based paclitaxel and carboplatin as firstline therapy in advanced non-small cell lung cancer. J Clin Oncol 2012, 30:2055-2060.
45. Hersh E., O'Day S., Ribas A., et al. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer 2010, 116:155-163.
46. Trieu V., Frankel T., Labao E., et al. SPARC expression in breast tumours may correlate to increased tumour distribution of nanoparticle albumin-bound paclitaxel (ABI-007) versus taxol. Proc Am Assoc Cancer Res 2005, 46. [abstract 5584].
47. Von Hoff D.D., Penny R., Shack S., et al. Frequency of potential therapeutic targets identified by immunohistochemistry (IHC) and DNA microarray (DMA) in tumours from patients who have progressed on multiple therapeutic agents. J Clin Oncol 2006, 24(Suppl. 3071):18s.
48. Hsiao Y.H., Lien H.C., Hwa H.L., et al. SPARC (osteonectin) in breast tumours of different histologic types and its role in the outcome of invasive ductal carcinoma. Breast J 2010, 16:305-308.
49. Nagai M.A., Gerhard R., Fregnani J.H., et al. Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients. Breast Cancer Res Treat 2011, 12:1-14.
50. Desai N.P., Trieu V., Hwang L.Y., et al. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs 2008, 19:899-900.
51. Sawyer M.B., Damaraju V.L., Mcquarrie S., et al. Cytotoxicity of nab-paclitaxel and SPARC expression in ovarian cell lines: an in vitro and in vivo study. J Clin Oncol 2011, 29(Suppl.). [abstr e13529].
52. Blackwell K.L., Hamilton E.P., Rocha G., et al. SPARC microenvironment signature (SMS) in patients treated with nab-paclitaxel/carboplatin (C)/bevacizumab(B) for triple-negative metastatic breast cancer (TNMBC). J Clin Oncol 2010, 28(Suppl.). [abstr e21040].
53. Desai N, Hwang L, Treece T, et al. SPARC microenvironment signature (SMS) as a prognostic biomarker when combined with LDH and plasma SPARC. Presented at the European Society of Medical Oncology (ESMO), Milan, Italy, October 08-12, 2010.
54. Inhorn R.C., Daniel B., Daniel D., et al. Correlation of SPARC, ER, PR, and HER2 tumour with progression-free survival from a phase II neoadjuvant trial of gemcitabine, epirubicin, and nabpaclitaxel. J Clin Oncol 2009, 27(Suppl.):15s. [abstr 618].
55. Infante J.R., Matsubayashi H., Sato N., et al. Peritumoural fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 2007, 25(3):319-325.
56. Sato N., Fukushima N., Maehara N., et al. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumour-stromal interactions. Oncogene 2003, 22:5021-5030.
57. Von Hoff D.D., Ramanathan R.K., Borad M.J., et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011, 29:4548-4550.
58. Hidalgo M., Von Hoff D.D. Translational therapeutic opportunities in ductal adenocarcinoma of the pancreas. Clin Cancer Res 2012, 18:4249-4250.
59. Neesse A., Frese K.K., Chan D.S., et al. SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice. Gut 2013, September 25 [Epub ahead of print].
60. Olive K., Jacobetz M., Davidson C., et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324:1457-1460.
61. Murakami M., Ernsting M.J., Undzys E., et al. Docetaxel conjugate nanoparticles that target α-smooth muscle actin-expressing stromal cells suppress breast cancer metastasis. Cancer Res 2013, 73(15):4862-4870.
62. Ibrahim N.K., Desai N., Legha S., et al. Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002, 8:1038-1040.
63. Nyman D.W., Campbell K.J., Hersh E., et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 2005, 23:7785-7790.
64. Ando M., Yonemori K., Katsumata N., et al. Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumours and metastatic breast cancer. Cancer Chemother Pharmacol 2012, 69:457-465.
65. Ibrahim N.K., Samuels B., Page R., et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 2005, 23:6019-6020.
66. Roy V., LaPlant B.R., Gross G.G., et al. North Central Cancer Treatment Group. Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nabpaclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Ann Oncol 2009, 20:449-453.
67. Somer B.G., Schwartzberg L.S., Arena F., et al. Phase II trial of nab-paclitaxel (nanoparticle albumin-bound paclitaxel (ABX))+capecitabine (XEL) in first-line treatment of metastatic breast cancer (MBC). J Clin Oncol 2007, 25(Suppl.):18s. [abstr 1053].
68. Danso M.A., Blum J.L., Robert N.J., et al. Phase II trial of weekly nab-paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer. J Clin Oncol 2008, 26(Suppl.). [abstr 1075].
69. Lobo C., Lopes G., Baez O., et al. Final results of a phase II study of nab-paclitaxel, bevacizumab and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat 2010, 123:427-435.
70. Conlin A.K., Hudis C.A., Bach A., et al. Randomized phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC). J Clin Oncol 2009, 27(Suppl.):15s. [abstr 1006].
71. Conlin A.K., Seidman A.D., Bach A., et al. Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. Clin Breast Cancer 2010, 10:281-287.
72. Mirtsching B., Corsgriff T., Harker G., et al. A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer. Clin Breast Cancer 2011, 11:121-128.
73. Tang L.C., Wang B.Y., Sun S., et al. Higher rate of skin rash in a phase II trial with weekly nanoparticle albumin-bound paclitaxel and cisplatin combination in Chinese breast cancer patients. BMC Cancer 2013, 13:232.
74. Gradishar W.J., Krasnojon D., Cheporov S., et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009, 27:3611-3620.
75. O'Shaughnessy J., Gradishar W.J., Bhar P., et al. Nab-paclitaxel for first-line treatment of patients with metastatic breast cancer and por prognostic factors: a retrospective analysis. Breast Cancer Res Treat 2013, 138:829-837.
76. Blum J.L., Savin M.A., Edelman G., et al. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer 2007, 7:850-856.
77. Guan Z., Feng F., Li Q.L., et al. Randomized study comparing nab-paclitaxel with solvent-based paclitaxel in Chinese patients (pts) with metastatic breast cancer (MBC). J Clin Oncol 2007, 25(Suppl.):18s. [abstr 1038].
78. Rugo H.S., Barry W.T., Moreno-Aspitia A., et al. CALGB 40502/NCCTG N063H: randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 2012, 30(Suppl.). [abstr CRA1002].
79. Lluch A., Alvarez I., Muñoz M., et al. Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors. Crit Rev Oncol Hematol 2014, 89(1):62-72.
80. Paz I.B., Lau S., Garberoglio C., et al. Nab-paclitaxel and carboplatin with or without trastuzumab (trast) as part of neoadjuvant chemotherapy (NCT) in patients (pts) with stage II-III breast cancer (BC). J Clin Oncol 2008, 26(Suppl.). [abstr 567].
81. Robidoux A., Buzdar A.U., Quinaux E., et al. A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer. Clin Breast Cancer 2010, 10:81-86.
82. Yardley D., Burris H., Peacock N., et al. A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer. Breast Cancer Res Treat 2010, 123:471-475.
83. Robert N., Krekow L., Stokoe C., et al. Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study. Breast Cancer Res Treat 2011, 125:115-120.
84. Pippen J., Paul D., Vukelja S., et al. Dose-dense doxorubicin and cyclophosphamide followed by dose-dense albumin-bound paclitaxel plus bevacizumab is safe as adjuvant therapy in patients with early stage breast cancer. Breast Cancer Res Treat 2011, 125:115-120.
85. Zhang D.S., Wang D.S., Wang Z.Q., et al. Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer. Cancer Chemother Pharmacol 2013, 71:1065-1070.
86. El-Khoueiry A.B., Iqbal S., Lenz H., et al. A phase I study of two different schedules of nab-Paclitaxel (Nab-p) with ascending doses of vandetanib (V) in patients (pts) with advanced solid tumours. J Clin Oncol 2010, 28(Suppl.):15s. [abstr 3059].
87. Ko A.H., Truong T.G., Kantoff E., et al. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer. Cancer Chemother Pharmacol 2012, 70:875-881.
88. Isacoff W.H., Reber H.A., Purcell F.M., et al. Low-dose continuous infusion 5-fluorouracil combined with weekly leucovorin, nab-Paclitaxel, oxaliplatin, and bevacizumab for patients with advanced pancreatic cancer: a pilot study. J Clin Oncol 2010, 28(Suppl.). [abstr e14545].
89. Ramanathan R.K., Lee P., Leach J.W., et al. Phase II study of induction therapy with gemcitabine and nab-paclitaxel followed by consolidation with mFOLFIRINOX in patients with metastatic pancreatic cancer. J Clin Oncol 2012, 30(Suppl. 34). [abstr 233].
90. Hosein P.J., de Lima Lopes G.D., Gomez C.M., et al. A phase II trial of nab-Paclitaxel in patients with advanced pancreatic cáncer who have progressed on gemcitabine-based therapy. Am J Clin Oncol 2013, 36:151-156.
91. Von Hoff D.D., Ervin T.J., Arena F.P., et al. Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). N Eng J Med 2013, 369(18):1691-1703.
92. Thapaliya P., Kundranda M.N., Curtis K.K., et al. Gemcitabine and nab-Paclitaxel in patients with unresectable/borderline resectable pancreatic cáncer. J Clin Oncol 2010, 28(Suppl.). [abstr e14675].
93. Olowokure O.O., Bedoya I.D., Mierzwa M.L., et al. Gemcitabine (G) plus nab-paclitaxel (nab-P) plus chemoradiation (CRT) in locally advanced pancreatic cancer (LAPC). J Clin Oncol 2012, 30(Suppl.). [abstr e14714].
94. Cooray P., Dean A.P. Neoadjuvant therapy with nanoparticle albumin-bound (nab)-paclitaxel to enhance the resectability of locally advanced pancreatic cancer (LAPC). J Clin Oncol 2012, 30(Suppl.). [abstr e14644].
95. Hartlapp I., Müller J., Kenn W., et al. Complete pathological remission of locally advanced, unresectable pancreatic cancer (LAPC) after intensified neadjuvant chemotherapy. Oncology 2013, 36:123-125.
96. Alvarez R., Musteanu M., Garcia-Garcia E., et al. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br J Cancer 2013, 109:926-933.
97. Stinchcombe T.E., Socinski M.A., Lee C.B., et al. Phase I trial of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with thoracic malignancies. J Thorac Oncol 2008, 3:521-526.
98. Green M.R., Manikhas G.M., Orlov S., et al. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small cell lung cancer. Ann Oncol 2006, 17:1263-1270.
99. Rizvi N.A., Riely G.J., Azzoli C.G., et al. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small cell lung cancer. J Clin Oncol 2008, 26:639-643.
100. Socinski M.A., Okamoto I., Hon J.K., et al. Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small cell lung cancer. Ann Oncol 2013, 24(9):2390-2396.
101. Ma W.W., Hidalgo M. The winning FORMULA-tion: the development of paclitaxel in pancreatic cancer. Clin Cancer Res 2013, 19(2):5572-5579.
102. Reynolds C., Barrera D., Jotte R., et al. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer. J Thorac Oncol 2009, 4:1537-1540.
103. Chang J.L., Ott P.A., Sorlie C., et al. Abraxane, temozolomide, and oblimersen (The ATG Trial): a final report of toxicity and clinical efficacy in metastatic melanoma patients with normal lactate dehydrogenase (LDH). J Clin Oncol 2011, 29(Suppl.). [abstr 8545].
104. Stinchcombe T.E., Socinski M.A., Walko C.M., et al. Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumours. Cancer Chemother Pharmacol 2007, 60:759-766.
105. Markovic S.N., Suman V.J., Kottschade L.A., et al. A phase II trial of carboplatin (C) and nab-paclitaxel (ABI-007-nab-P) in patients with unresectable stage IV melanoma: final data from N057E. J Clin Oncol 2009, 27(Suppl.):15s. [abstr 9055].
106. Boasberg P.D., Weber R.W., Cruickshank S., et al. Phase II trial of nab-paclitaxel and bevacizumab as first-line therapy in patients with unresectable melanoma. J Clin Oncol 2011, 29(Suppl.). [abstr 8543].
107. Kottschade L.A., Suman V., Perez D.G., et al. A randomized Phase II trial of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV metastatic melanoma: a North Central Cancer Treatment Group Study, N0775. J Clin Oncol 2011, 29(Suppl.). [abstr 8532].
108. Hersh E., Del Vecchio M., Brown M., et al. Phase 3, randomized, open-label, multicenter trial of nab-paclitaxel versus dacarbazine in previously untreated patients with metastatic malignant melanoma. Pigment Cell Melanoma Res 2012, 25:863.
109. Benigno B.B., Burrell M.O., Daugherty P., et al. A phase II nonrandomized study of nab-paclitaxel plus carboplatin in patients with recurrent platinum-sensitive ovarian or primary peritoneal cancer. J Clin Oncol 2010, 28(Suppl.):15s. [abstr 5011].
110. Teneriello M.G., Tseng P.C., Crozier M., et al. Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer. J Clin Oncol 2009, 27:1426-1430.
111. Coleman R.L., Brady W.E., McMeekin D.S., et al. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 2011, 122:111-115.
112. Tillmanns T.D., Lowe M.P., Schwartzberg L.S., et al. A Phase 2 study of bevacizumab with nab-paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma. J Clin Oncol 2010, 28(Suppl.):15s. [abstr 5009].
113. Grivas P.D., Hussain M., Hafez K., et al. A phase II trial of neoadjuvant nab-paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder. Urology 2013, 82(1):111-117.
114. Ko Y.J., Canil C.M., Mukherjee S.D., et al. Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study. Lancet Oncol 2013, 14:169-176.
115. Liesveld J., Asselin B. It's ALL in the liposomes: vincristine gets a newpackage. J Clin Oncol 2013, 31:657-659.
116. Foote M. Using nanotechnology to improve the characteristics of antineoplastic drugs: improved characteristics of nab-paclitaxel compared with solvent-based paclitaxel. Biotechnol Annu Rev 2007, 13:345-357.
117. Hidalgo M. Pancreatic cancer. N Engl J Med 2010, 362(17):1605-1610.
118. Kelleher F.C. Hedgehog signaling and therapeutics in pancreatic cáncer. Carcinogenesis 2011, 32(4):445-451.
119. Maitra A, Rajeshkumar NV, Rudek M, et al. Nab-Paclitaxel targets tumour stroma and results, combined with gemcitabine in high efficacy against pancreatic cáncer models. Presented at the AACR-NCI-EORTC international conference on molecular targets and cancer therapeutics. Boston, MA, November 15-19; 2009.
120. Frese K.K., Neesse A., Cook N., et al. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov 2012, 2:260-269.
121. Commisso C., Davidson S.M., Soydaner-Azeloglu R.G., et al. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature 2013, 497(7451):633-637.
122. Liu H., Tekle C., Chen Y.W., et al. B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation. Mol Cancer Ther 2011, 10(6):960-971.
123. Rajput S., Volk-Draper L.D., Ran S. TLR4 is a novel determinant of the response to paclitaxel in breast cancer. Mol Cancer Ther 2013, 12(8):1676-1680.